Answers are grounded in this paper and cite their sources.
Shows enhanced hemostasis in thrombocytopenic patients with platelet substitutes, indicating potential clinical benefits.
FPH significantly improved hemostasis in ex vivo samples from thrombocytopenic patients, both before and after PC transfusion, as measured by T-TAS 01. The findings support the potential role of T-TAS 01 in evaluating not only conventional platelet transfusions but also emerging platelet substitutes, such as FPH, for clinical use.
No takes yet. Share an insight, caveat, or question.
Samanbar et al. (2026) studied this question.